MétaCan
Menu
Back to cohort
Record W3013924915 · doi:10.1016/j.annonc.2020.02.011

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

2020· article· en· W3013924915 on OpenAlexafffund
M.C. Liu, Geoffrey R. Oxnard, Eric A. Klein, Charles Swanton, Michael V. Seiden, Minetta C. Liu, David A. Smith, Donald Richards, Timothy J. Yeatman, Allen Lee Cohn, Rosanna L. Lapham, Jessica Clément, Alexander S. Parker, Mohan K. Tummala, Kristi McIntyre, Mikkael A. Sekeres, Alan H. Bryce, Robert D. Siegel, Xuezhong Wang, David Cosgrove, Nadeem R. Abu‐Rustum, Jonathan C. Trent, David D. Thiel, Carlos Becerra, Manish Agrawal, Lawrence Garbo, Jeffrey K. Giguere, Ross M. Michels, Ronald P. Harris, Stephen Richey, Timothy A. McCarthy, David Waterhouse, Fergus J. Couch, Sharon Wilks, Amy Krie, Rama Balaraman, Álvaro Restrepo, Michael W. Meshad, Kimberly Rieger‐Christ, Travis Sullivan, Christine Lee, Daniel Greenwald, William Oh, Che‐Kai Tsao, Neil Fleshner, Hagen F. Kennecke, Maged Khalil, David R. Spigel, Atisha Manhas, Brian Ulrich, P. Kovoor, Christopher Stokoe, Jay Courtright, Habte Yimer, Timothy Larson, Steven R. Cummings, Farnaz Absalan, Gregory E. Alexander, Brian C. Allen, Hamed Amini, Alexander M. Aravanis, Siddhartha Bagaria, Leila Bazargan, John F. Beausang, Jennifer R. Berman, Craig Betts, Alexander W. Blocker, Joerg Bredno, Robert Calef, Gordon Cann, Jeremy G. Carter, Christopher Chang, Hemanshi Chawla, Xiaoji Chen, Tom C. Chien, Daniel Civello, Konstantin Davydov, Vasiliki Demas, Dong Zhao, Saniya Fayzullina, Alexander P. Fields, Darya Filippova, Peter Freese, Eric T. Fung, Sante Gnerre, Samuel Gross, Meredith Halks‐Miller, Megan P. Hall, Anne‐Renee Hartman, Chenlu Hou, Earl Hubbell, Nathan Hunkapiller, Karthik A. Jagadeesh, Arash Jamshidi, Roger Jiang, Byoungsok Jung, Tae‐Hyung Kim, Richard D. Klausner, Kathryn N. Kurtzman, Mark Lee, Wendy Lin, Jafi A. Lipson, Hai Liu, Qin‐Wen Liu, Margarita Lopatin, Tara Maddala, M. Cyrus Maher, Collin Melton, Andrea Mich, Shivani Nautiyal, Jonathan Newman, Joshua Newman, Virgil Nicula, Cosmos Nicolaou, Ongjen Nikolic, Wenying Pan, Shilpen Patel, Sarah A. Prins, Richard P. Rava, Neda Ronaghi, Onur Sakarya, Ravi Vijaya Satya, Jan Schellenberger, Eric Scott, Amy J. Sehnert, Rita Shaknovich, Avinash Shanmugam, K. C. Shashidhar, Ling Shen, Archana Shenoy, Seyedmehdi Shojaee, Pranav Singh, Kristan K. Steffen, Susan Tang, Jonathan Toung, Anton Valouev, Oliver Venn, Richard T. Williams, Tony Wu, Hui Xu, Christopher Yakym, Xiao Yang, Jessica L. Yecies, Alexander S. Yip, Jack Youngren, Jeanne Yue, Jingyang Zhang, Lily Zhang, Lori Zhang, Nan Zhang, Christina Curtis, Donald A. Berry

Bibliographic record

VenueAnnals of Oncology · 2020
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer Genomics and Diagnostics
Canadian institutionsPrincess Margaret Cancer CentreUniversity of Toronto
FundersRosetrees TrustNational Cancer InstituteCancer Research UKFrancis Crick InstituteWellcome TrustUniversity Health NetworkMedical Research CouncilWellcomeCRUK Lung Cancer Centre of ExcellenceBreast Cancer Research Foundation
KeywordsMedicineDNA methylationCell-free fetal DNADNAComputational biologyCancer researchGeneticsGeneGene expressionBiology

Abstract

fetched live from OpenAlex

BACKGROUND: Early cancer detection could identify tumors at a time when outcomes are superior and treatment is less morbid. This prospective case-control sub-study (from NCT02889978 and NCT03085888) assessed the performance of targeted methylation analysis of circulating cell-free DNA (cfDNA) to detect and localize multiple cancer types across all stages at high specificity. PARTICIPANTS AND METHODS: The 6689 participants [2482 cancer (>50 cancer types), 4207 non-cancer] were divided into training and validation sets. Plasma cfDNA underwent bisulfite sequencing targeting a panel of >100 000 informative methylation regions. A classifier was developed and validated for cancer detection and tissue of origin (TOO) localization. RESULTS: Performance was consistent in training and validation sets. In validation, specificity was 99.3% [95% confidence interval (CI): 98.3% to 99.8%; 0.7% false-positive rate (FPR)]. Stage I-III sensitivity was 67.3% (CI: 60.7% to 73.3%) in a pre-specified set of 12 cancer types (anus, bladder, colon/rectum, esophagus, head and neck, liver/bile-duct, lung, lymphoma, ovary, pancreas, plasma cell neoplasm, stomach), which account for ∼63% of US cancer deaths annually, and was 43.9% (CI: 39.4% to 48.5%) in all cancer types. Detection increased with increasing stage: in the pre-specified cancer types sensitivity was 39% (CI: 27% to 52%) in stage I, 69% (CI: 56% to 80%) in stage II, 83% (CI: 75% to 90%) in stage III, and 92% (CI: 86% to 96%) in stage IV. In all cancer types sensitivity was 18% (CI: 13% to 25%) in stage I, 43% (CI: 35% to 51%) in stage II, 81% (CI: 73% to 87%) in stage III, and 93% (CI: 87% to 96%) in stage IV. TOO was predicted in 96% of samples with cancer-like signal; of those, the TOO localization was accurate in 93%. CONCLUSIONS: cfDNA sequencing leveraging informative methylation patterns detected more than 50 cancer types across stages. Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.016

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.005
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.054
GPT teacher head0.328
Teacher spread0.274 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1,509
Published2020
Admission routes2
Has abstractyes

Explore more

Same venueAnnals of OncologySame topicCancer Genomics and DiagnosticsFrench-language works237,207